Blinatumomab, Inotuzumab Ozogamicin, and Chemotherapy for Acute Lymphoblastic Leukemia
Phase 2
80
about 10 years
14+
1 site in TX
About this study
This trial is testing if blinatumomab, inotuzumab ozogamicin, and combination chemotherapy are effective as the first treatment for patients with B acute lymphoblastic leukemia. This new approach may offer a better chance of success than standard chemotherapy alone.
Based on ClinicalTrials.gov records.
What participants do
- 1.Laboratory Biomarker Analysis
- 2.Receive Blinatumomab
- 3.Receive Inotuzumab Ozogamicin
- +3 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
blinatumomab, cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), cytarabine, dexamethasone, Antineoplastic Agent [TC] (Topoisomerase 2 Inhibitors), inotuzumab ozogamicin, mercaptopurine, methotrexate
injection, intravenous, infusion, injection (Injection), ocular, oral (Oral Tablet), oral
Primary: Relapse-free survival (RFS)
Secondary: Incidence of adverse events, Overall response rate, Overall survival
Oncology